Gilead slapped with US subpoena on manufacturing, distribution practices
This article was originally published in Scrip
Executive Summary
The market reacted only mildly to a subpoena Gilead Sciences received from the US Attorney's Office for the Northern District of California requesting documents related to the manufacture and related quality and distribution practices of several of the firm's drugs used to treat HIV/AIDS, pulmonary arterial hypertension and chronic hepatitis B.